Fewer than 10% of people eligible to benefit from obesity jabs such as Wegovy have access to them, caution the global health agency as it issues its first recommendations on the therapies.
Given in excess of 1,000,000,000 people worldwide currently living with obesity, it is calling for more widespread and fairer availability to these injectable treatments.
According to projections, over two billion could be obese by 2030 unless action is taken.
"The latest guidelines affirms that obesity is a lifelong illness that can be treated with thorough and ongoing treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and distribution challenges are key obstacles to universal access to the injections that can aid individuals in losing significant weight, notes the organization.
Skinny Jab Shortage
Despite the current most favorable case, the production of these medications would only suffice for approximately 100 million people – less than 10% of the global need, per the health organization.
The advice encourages governments and firms to widen access, by strategies such as patent sharing.
Exclusive production rights on a key compound – the primary ingredient of the drug Wegovy – is scheduled to end in multiple nations in 2026.
The Way Obesity Drugs Operate
These medications imitate a biological compound to delay gastric emptying, suppress the appetite and increase feelings of fullness so individuals eat less.
Patients usually see weight reduction after several weeks of commencing the once-weekly jabs.
Evidence suggests patients may regain a significant portion a year later of discontinuing the medication, as their normal food cravings come back.
To be above a healthy weight raises your chance for developing diseases, like diabetes, cardiovascular issues, brain attack, and specific cancers.
Excess weight concerns people in all nations and was responsible for over three and a half million deaths worldwide in 2024, according to the WHO.
